annotations:
  0:
    partial: false
    structured:
      - object: CHD Death
      - object: Non-fatal MI
      - object: Ischemic Stroke
  1:
    partial: true
    structured:
      - object: Acute Febrile Illness
        time: 7-day Period Following the Onset
        measure: Number
  2:
    partial: true
    structured:
      - object: Alanine Aminotransferase (ALT)
        measure: Percentage of Participants
        range: More Than 1.5 Times Upper Limit of Normal
        range_norm: Above Normal
      - object: Aspartate Aminotransferase (AST)
        measure: Percentage of Participants
        range: More Than 1.5 Times Upper Limit of Normal
        range_norm: Above Normal
  3:
    partial: false
    structured:
      - object: CD4/CD8 Cell Counts
        measure: Mean Change From Baseline
  4:
    partial: true
    structured:
      - object: Dasatinib
        measure: Number of Subjects
        measure_norm: Number of Participants
  5:
    partial: true
    structured:
      - object: Costs for Referrals
  6:
    partial: true
    structured:
      - object: Duration of Solicited Local Symptoms
        time: After Vaccination
  7:
    partial: false
    structured:
      - object: Partial Onset Seizures (Type I)
        measure: Percentage of Responder Subjects
        time: Up-titration Period
  8:
    partial: true
    structured:
      - object: Leibowitz Social Anxiety Scale (LSAS) Total Score
        measure: Change From Baseline
        time: 1-Month
  9:
    partial: true
    structured:
      - object: Area Under the Plasma Concentration-time Curve
  10:
    partial: false
    structured:
      - object: Transitional Dyspnea Index (TDI) Score
  11:
    partial: true
    structured:
      - object: Survival
        time: Step 1
  12:
    partial: true
    structured:
      - object: Equivalence of Seroprotection Against Poliovirus
        time: After Vaccination
  13:
    partial: true
    structured:
      - object: Vital Sign Parameter of Heart Rate
        time: During the Double-blind Treatment Period
        measure: Change From Baseline
  14:
    partial: true
    structured:
      - object: Safety
        time: Who Have Recently Quit Smoking
      - object: Tolerability
        time: Who Have Recently Quit Smoking
  15:
    partial: false
    structured:
      - object: Anxiety Symptoms
        measure: Change
  16:
    partial: false
    structured:
      - object: Lipids
  17:
    partial: true
    structured:
      - object: Invasive Ventilator-Free Survival
        measure: Number of Participants
  18:
    partial: true
    structured:
      - object: Social Function Domain Score
        time: Baseline
      - object: Social Function Domain Score
        time: Weeks 6
      - object: Social Function Domain Score
        time: Weeks 14
  19:
    partial: true
    structured:
      - object: Achieved Platelet Engraftment
        time: By Day 12 But No Later Than Day 21
        measure: Number of Transplants
  20:
    partial: false
    structured:
      - object: Subjective Sleep Onset Latency
        measure: Change From Baseline
        time: Month 6
  21:
    partial: false
    structured:
      - object: Operator Satisfaction
        specifier: With Manual Device and Powered Device
  22:
    partial: false
    structured:
      - object: Trough FEV1 Response
        time: Week 6
  23:
    partial: false
    structured:
      - object: Blood Eosinophils (Cells/uL)
        time: Week 52
        measure: Mean Change from Baseline
  24:
    partial: true
    structured:
      - object: Grade 3-4 Hematology Abnormalities
        specifier: Occurring in >=5% Participants
        measure: Number of Participants
  25:
    partial: false
    structured:
      - object: Plasma Concentration
        specifier: Cycle 1/Day 25
        measure: Maximum Observed
  26:
    partial: false
    structured:
      - object: Diabetes
        measure: Quantitative Change
  27:
    partial: false
    structured:
      - object: Serum Iron
  28:
    partial: true
    structured:
      - object: Number of Glucose-Lowering Treatments 
        time: Weeks 12 and 24
        measure: Absolute Change From Baseline
  29:
    partial: false
    structured:
      - object: Occurrence of Treatment-emergent Adverse Events
      - object: Severity of Treatment-emergent Adverse Events
  30:
    partial: false
    structured:
      - object: Best Overall Response Rate
  31:
    partial: false
    structured:
      - object: Difference Between Groups (HBO Minus HBA)
        measure: Change in Scores
        specifier: "Pediatric Evaluation of Disability Inventory (PEDI) Functional Skills: Social Function"
        time: Post-treatment Minus Pre-treatment
  32:
    partial: false
    structured:
      - object: Clinical Global Impression Improvement Score
        measure: Percentage of Participants 
        time: Week 26
  33:
    partial: false
    structured:
      - object: Descend Steps
        time: Pre-Intervention
  34:
    partial: false
    structured:
      - object: Maximum Severity
        measure: Number of Participants
        specifier: Each stage
  35:
    partial: true  # at Least 10mm
    structured:
      - object: Difference in VAS Pain Scale Scores
        measure: Proportion of the Subjects
        specifier: Within the Subject (VAS of the Control Medical Device - VAS of the Test Medical Device) 
        time: Immediately After Treatment
  36:
    partial: false  # at Least 10mm
    structured:
      - object: Adinopectin
        measure: Adjusted Mean Change
        time: Week 52
  37:
    partial: true  # Visit 4
    structured:
      - object: HAQ-DI
        measure: Change From Baseline
        time: Month 6
  38:
    partial: true  
    structured:
      - object: Adverse Events
        measure: Number
        time: Week 0-52
  39:
    partial: false 
    structured:
      - object: Meeting the Criteria of the American College of Rheumatology for 20% Improvement
        measure: Percentage of Participants
  40:
    partial: false 
    structured:
      - object: TEAEs
        measure: Number of Participants
      - object: Grade >= 3 TEAEs
        measure: Number of Participants
      - object: Serious TEAEs
        measure: Number of Participants
      - object: Treatment Related TEAEs
        measure: Number of Participants
  41:
    partial: false 
    structured:
      - object: Buccal Cells Demonstrating a Decline in Cyclin D1
        measure: Number of Patients
  42:
    partial: false  
    structured:
      - object: Self-Reported Spray Doses
        measure: Maximum Total Daily Number
        time: Week 17
  43:
    partial: false
    structured:
      - object: Infant Sleep Quantity
        measure: Change
  44:
    partial: false
    structured:
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 3 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 6 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 9 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 12 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 18 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 24 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 30 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 36 Months
      - object: Emotional Well-Being (EWB) Subscale Score
        measure: Change From Baseline
        time: 48 Months
  45:
    partial: false 
    structured:
      - object: Adverse Events
        measure: Percentage of Participants
        time: Within 1 Month After Dose 2
  46:
    partial: false 
    structured:
      - object: PIK3CA Mutation
        measure: Number of Participants
        time: Baseline
  47:
    partial: true 
    structured:
      - object: eSAGE Score
  48:
    partial: true
    structured:
      - object: Visual Analog Pain Scale
  49:
    partial: true
    structured:
      - object: Severity Total Score
        time: Weeks 0
      - object: Severity Total Score
        time: Weeks 2
      - object: Severity Total Score
        time: Weeks 4
      - object: Severity Total Score
        time: Weeks 5
      - object: Severity Total Score
        time: Weeks 6
      - object: Severity Total Score
        time: Weeks 8
      - object: Severity Total Score
        time: Weeks 12
      - object: Severity Total Score
        time: Weeks 16
      - object: Severity Total Score
        time: Weeks 20
      - object: Severity Total Score
        time: Weeks 24
      - object: Severity Total Score
        time: Weeks 28
      - object: Severity Total Score
        time: Weeks 32
      - object: Severity Total Score
        time: Weeks 36
      - object: Severity Total Score
        time: Weeks 40
      - object: Severity Total Score
        time: Weeks 44
      - object: Severity Total Score
        time: Weeks 48
      - object: Severity Total Score
        time: Weeks 52   # EW meaning?
  50:
    partial: false
    structured:
      - object: Patient Satisfaction
        time: 3 Months
  51:
    partial: false
    structured:
      - object: Corneal Staining Score
        measure: Mean
  52:
    partial: true
    structured:
      - object: ELISA Antibody
        measure: Percentage of Subjects
        range: Rise
  53:
    partial: false
    structured:
      - object: Elvitegravir Concentration
        measure: Change
        specifier: In Penile Secretions
  54:
    partial: false
    structured:
      - object: PTSD Symptoms
        measure: Change
        specifier: As Measured by the PCL
  55:
    partial: true # non-serotype specific?
    structured:
      - object: Dengue Viremia
        measure: Number of Cases
        time: Following Vaccination
      - object: Dengue Viremia
        measure: Number of Cases
        time: Following Placebo
  56:
    partial: false
    structured:
      - object: Adverse Events
        measure: Number of Participants
        specifier: High-Grade (Grade 3-4) Immune Mediated
  57:
    partial: false
    structured:
      - object: Pain Intensity and TBW
        measure: Correlation between Change
        time: 15 Minutes Post-treatment
  58:
    partial: true
    structured:
      - object: Area Under the Plasma Concentration-time Curve
        time: From time 0
  59:
    partial: true
    structured:
      - object: MSIS-29 Psychological Score
        measure: Change From Baseline
        time: Months 3
      - object: MSIS-29 Psychological Score
        measure: Change From Baseline
        time: Months 6
      - object: MSIS-29 Psychological Score
        measure: Change From Baseline
        time: Months 9
      - object: MSIS-29 Psychological Score
        measure: Change From Baseline
        time: Months 12
  60:
    partial: false
    structured:
      - object: Implant Insertion Time
        unit: Seconds
  61:
    partial: true
    structured:
      - object: Confirmed Best Objective Response
        measure: Percentage of Participants
        specifier: Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
  62:
    partial: true
    structured:
      - object: Treatment-emergent Resistance-associated Substitutions
        measure: Percentage of Participants
        time: Week 49
        specifier: From the Pooled Treatment Group
  63:
    partial: false
    structured:
      - object: Follow-up Visits
        measure: Change From Baseline
        specifier: in Exercise Tolerance
  64:
    partial: true
    structured:
      - object: Associations Between Polymorphisms
        specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically 
      - object: Efficacy
        specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically 
      - object: Toxicities
        specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically 
  65:
    partial: false
    structured:
      - object: Patients Treated With Pentamidine
        measure: Response Rate # in, of ambiguous?
  66:
    partial: false
    structured:
      - object: Area Under Curve
        specifier: Over a Uniform Dosing Interval Tau
        time: at Steady State
  67:
    partial: false
    structured:
      - object: Heartburn-Free 24-hour Days
        measure: Percentage
  68:
    partial: true
    structured:
      - object: Triiodothyronine # how to know that it is a lab result?
        measure: Change From Baseline
  69:
    partial: false
    structured:
      - object: Worst Case Body Temperature Values
        measure: Number of Participants
        specifier: of PCI
  70:
    partial: true
    structured:
      - object: Systolic Blood Pressure
        range: <90 mmHg
        time: Within 30 minutes
        measure: Percentage of Patients
  71:
    partial: true
    structured:
      - object: Abnormal Glycosylated Hemoglobin Value
        measure: Number of Participants
  72:
    partial: false
    structured:
      - object: REGN10933 Concentration
        specifier: in Serum
  73:
    partial: false
    structured:
      - object: Surgical Site
        measure: Occurrence Rate
  74:
    partial: false
    structured:
      - object: Forced Vital Capacity
        measure: Annual Rate of Decline
  75:
    partial: false
    structured:
      - object: Maternal Morbidity
  76:
    partial: false
    structured:
      - object: CD22 Expression Levels
        specifier: From Peripheral Blood by Best Response
  77:
    partial: true # category
    structured:
      - object: Basophils
        measure: Change
  78:
    partial: false
    structured:
      - object: Rescue Medication
        specifier: Observed Data
        time: Week 64
        measure: Number of Participants
  79:
    partial: false 
    structured:
      - object: Pathogen 
        specifier: Identified by the Karius Test and Standard Culture Methods
        time: at Time Point IP2
        measure: Number of Participants
  80:
    partial: true
    structured:
      - object: Time to Need for Antibiotics 
        specifier: Inhaled Antipseudomonal for Respiratory Event
      - object: Time to Need for Antibiotics
        specifier: IV Antipseudomonal for Respiratory Event
  81:
    partial: false
    structured:
      - object: Incidence of Cervical Intraepithelial Neoplasia
        specifier: Associated With High-risk HPV Types Other Than 16/18 in Participants >26 Years of Age
  82:
    partial: false
    structured:
      - object: SBP
        measure: Combined Mean Change
        time: from Baseline to Week 6
        specifier: Mean by Patient
      - object: SBP
        measure: Combined Mean Change
        time: from Baseline to Week 8
        specifier: Mean by Patient
  83:
    partial: false
    structured:
      - object: Safety
        specifier: Peptide Vaccines
  84:
    partial: false
    structured:
      - object: Low Density Lipoprotein Cholesterol
        measure: Percent Change From Baseline
        time: Week 12
  85:
    partial: true
    structured:
      - object: Hot Flash Related Daily Interference Scale
  86:
    partial: false
    structured:
      - object: Mean Worse Eye Intraocular Pressure
        specifier: Analyzed by Mixed-Effect Model for Repeated Measure
        measure: Change From Baseline
  87:
    partial: false
    structured:
      - object: Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC) 
        specifier: the Target Knee by qMRI 
        time: Week 52
        measure: Change From Baseline
  88:
    partial: true
    structured:
      - object: Brief Fatigue Inventory (BFI) Worst Fatigue Score
        measure: Change From Baseline
  89:
    partial: false
    structured:
      - object: Ketamine
        measure: AUC # normalize: area under curve # https://arxiv.org/pdf/2311.08921 # https://arxiv.org/pdf/2406.04528 # https://netraneupane.medium.com/gliner-zero-shot-ner-outperforming-chatgpt-and-traditional-ner-models-1f4aae0f9eef
  90:
    partial: false
    structured:
      - object: Recurrent Disease
        measure: Percentage of Participants
  91:
    partial: false
    structured:
      - object: Progression-free Survival 
        time: 36 Months 
        specifier: Among Patients Who Are PET Positive After Induction Treatment
  92:
    partial: false
    structured:
      - object: Health Assessment Questionnaire-Disability Index Changes
        time: From Week 24 at Week 48
        specifier: in Patients Treated Continuously With GP2017 and in Patients Treated With GP2017 After Switch From Humira
  93:
    partial: false
    structured:
      - object: Snack Added Sugars Purchased
        time: Week 1
  94:
    partial: false
    structured:
      - object: Overall Survival
        measure: Number of Participants
  95:
    partial: false
    structured:
      - object: Knee Injury and Osteoarthritis Outcome Score Pain sub scores
        measure: Change From Baseline
      - object: Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living
        measure: Change From Baseline
  96:
    partial: false
    structured:
      - object: Suppression of Plasma Renin Activity
        measure: Magnitude
        specifier: From Low Sodium to High Sodium Diets
  97:
    partial: false
    structured:
      - object: Terminal Half-life
        specifier: Metabolite PR-389/M14
  98:
    partial: false
    structured:
      - object: Trichiasis Severity Levels
        time: 3-6 Months
        measure: Number of Eyelids
  99: # Effect of SPN-810 on Retrospective-Modified Overt Aggression Scale (R-MOAS) Remission Rate
    partial: true
    structured:
      - object: Remission Rate
        specifier: Retrospective-Modified Overt Aggression Scale (R-MOAS)




    

  


      
      



      
    